Rallybio (RLYB) Research & Development (2020 - 2026)
Rallybio (RLYB) posted Research & Development of $2.9 million for Q1 2026, down 21.45% sequentially from $3.7 million in Q4 2025, and down 49.85% YoY from $5.7 million in Q1 2025.
Rallybio (RLYB) Research & Development (2020 - 2026) Analysis & Trends
Rallybio has reported Research & Development for 7 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Research & Development fell 49.85% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (down 51.18% YoY) and the FY2025 annual result came in at $19.6 million, down 52.79% from the prior year.
- Research & Development declined to $2.9 million in Q1 2026 per RLYB's latest filing, from $3.7 million in the prior quarter.
- Over five years, Research & Development peaked at $15.9 million in Q4 2023 and troughed at -$26.8 million in Q4 2022.
- A 5-year average of $7.1 million and a median of $8.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development sank 539.71% in 2022, then soared 159.43% in 2023.
- Over 5 years, Research & Development stood at -$26.8 million in 2022, then jumped by 159.43% to $15.9 million in 2023, then plunged by 53.62% to $7.4 million in 2024, then sank by 50.51% to $3.7 million in 2025, then decreased by 21.45% to $2.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $2.9 million, $3.7 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 758,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 758,000.00 |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 3.66 Mn |
| Sep 30, 2025 | 4.14 Mn |
| Jun 30, 2025 | 6.07 Mn |
| Mar 31, 2025 | 5.73 Mn |
| Dec 31, 2024 | 7.39 Mn |
| Sep 30, 2024 | 8.24 Mn |
| Jun 30, 2024 | 12.95 Mn |
| Mar 31, 2024 | 12.94 Mn |
| Dec 31, 2023 | 15.92 Mn |
| Sep 30, 2023 | 13.29 Mn |
| Jun 30, 2023 | 13.13 Mn |
| Mar 31, 2023 | 11.20 Mn |
| Dec 31, 2022 | -26.80 Mn |
| Sep 30, 2022 | 12.11 Mn |
| Jun 30, 2022 | 10.14 Mn |
| Mar 31, 2022 | 7.65 Mn |
| Dec 31, 2021 | 6.09 Mn |
| Sep 30, 2021 | 4.96 Mn |